Storage: Store at or below -20 ºC.
Solubility: Soluble in DMSO at 65 mg/mL; soluble in ethanol at 10 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.
Disposal: A.

Bexarotene (LGD-1069) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids. It is an oral, noncytotoxic drug that was approved in Europe and in the U.S.A. for the treatment of refractory advanced-stage cutaneous T-cell lymphomas (CTCL). Gniadecki, R., et al. "The optimal use of bexarotene in cutaneous T-cell lymphoma." Br. J. Dermatol. 157: 433-440 (2007).

A mouse model of Alzheimer's disease was treated with oral administration of bexarotene, a retinoid X receptor agonist. Bexarotene treatment significantly enhanced the clearance of soluble β-amyloid (Aβ) from the brain within hours in an apolipoprotein E-dependent manner. It reduced Aβ plaque area more than 50% within just 72 hours. Bexarotene treatment also resulted in the rapid reversal of cognitive, social, and olfactory deficits and improved neural circuit function. Cramer, P.E., et al. "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models." Science 335: 1503-1506 (2012).

Bexarotene is the active ingredient in the drug sold under the trade name Targretin®, which has been approved in at least one country for treatment of patients with CTCL. NOTE: The bexarotene sold by LC Laboratories is NOT Targretin®, and is NOT for human use.

Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.

This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

Not available in some countries; not available to some institutions; not available for some uses.